MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
<jats:p>Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, op...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Proceedings of the National Academy of Sciences
2023
|
| Online Access: | https://hdl.handle.net/1721.1/147778 |
| _version_ | 1811093306232274944 |
|---|---|
| author | Stopfer, Lauren E Rettko, Nicholas J Leddy, Owen Mesfin, Joshua M Brown, Eric Winski, Shannon Bryson, Bryan Wells, James A White, Forest M |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Stopfer, Lauren E Rettko, Nicholas J Leddy, Owen Mesfin, Joshua M Brown, Eric Winski, Shannon Bryson, Bryan Wells, James A White, Forest M |
| author_sort | Stopfer, Lauren E |
| collection | MIT |
| description | <jats:p>Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition (MEKi) alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes in the peptide major histocompatibility molecules (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1,000 copies per cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting four epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest.</jats:p> |
| first_indexed | 2024-09-23T15:43:10Z |
| format | Article |
| id | mit-1721.1/147778 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T15:43:10Z |
| publishDate | 2023 |
| publisher | Proceedings of the National Academy of Sciences |
| record_format | dspace |
| spelling | mit-1721.1/1477782023-02-01T03:07:02Z MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas Stopfer, Lauren E Rettko, Nicholas J Leddy, Owen Mesfin, Joshua M Brown, Eric Winski, Shannon Bryson, Bryan Wells, James A White, Forest M Massachusetts Institute of Technology. Department of Biological Engineering <jats:p>Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition (MEKi) alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes in the peptide major histocompatibility molecules (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1,000 copies per cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting four epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest.</jats:p> 2023-01-30T15:01:43Z 2023-01-30T15:01:43Z 2022-12-06 2023-01-30T14:48:19Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/147778 Stopfer, Lauren E, Rettko, Nicholas J, Leddy, Owen, Mesfin, Joshua M, Brown, Eric et al. 2022. "MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas." Proceedings of the National Academy of Sciences, 119 (49). en 10.1073/pnas.2208900119 Proceedings of the National Academy of Sciences Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Proceedings of the National Academy of Sciences PNAS |
| spellingShingle | Stopfer, Lauren E Rettko, Nicholas J Leddy, Owen Mesfin, Joshua M Brown, Eric Winski, Shannon Bryson, Bryan Wells, James A White, Forest M MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas |
| title | MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas |
| title_full | MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas |
| title_fullStr | MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas |
| title_full_unstemmed | MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas |
| title_short | MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas |
| title_sort | mek inhibition enhances presentation of targetable mhc i tumor antigens in mutant melanomas |
| url | https://hdl.handle.net/1721.1/147778 |
| work_keys_str_mv | AT stopferlaurene mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT rettkonicholasj mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT leddyowen mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT mesfinjoshuam mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT browneric mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT winskishannon mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT brysonbryan mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT wellsjamesa mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas AT whiteforestm mekinhibitionenhancespresentationoftargetablemhcitumorantigensinmutantmelanomas |